Compare Ascendis Pharma A/S (ASND) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs SMX Security Matters plc — how do they compare? Ascendis Pharma A/S trades at $263 (market cap $17.74B), while SMX Security Matters plc trades at $16.58 (market cap $15.03M). The key difference: Ascendis Pharma A/S is far larger — about 1180.3× SMX Security Matters plc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| ASND | SMX | |
|---|---|---|
Market Cap | $17.74B | $15.03M |
Sector | Health | Technology |
52-Week High | $277.18 | $313.26K |
52-Week Low | $163.32 | $12.87 |
Enterprise Value | $18.11B | $12.00M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SMX trades at $15.65, down 4.02% in the last session, with a neutral technical signal and bearish moving averages. The stock shows negative profitability with a ROE of -2,216.26% and ROA of -398.22%, while the P/B ratio stands at 1.7. Recent corporate actions include two reverse stock splits in May and June 2026. News highlights the company's focus on recycled plastic traceability amid new state recycling mandates, positioning it in a growing regulatory environment.
The outlook for SMX is challenged by weak profitability but supported by potential demand from recycling regulations. Investment opportunity lies in policy-driven adoption of its traceability technology, while risks include execution hurdles and sustained negative returns. The stock's near-term direction may hinge on converting regulatory tailwinds into tangible financial improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
